European journal of neurology · 2025
Is a Novel Transthyretin Gene Mutation Associated With Cerebral Amyloid Angiopathy?
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Camilla Strazzabosco, Giulia Marinoni, Benedetta Storti, Francesca Balistreri, Stefania Magri, Giuliana Pollaci, Gemma Gorla, Laura Gatti, Anna Bersano
Аннотация
OBJECTIVES: To report a case of a novel variant of the TTR gene associated with Cerebral Amyloid Angiopathy (CAA), thereby expanding the spectrum of TTR-related amyloidosis.
METHODS: A 56-year-old man presented with a history of right fronto-parietal intracerebral haemorrhage and recurrent transient episodes of right arm paraesthesia. Based on clinical and radiological presentation, a probable CAA diagnosis was established according to Boston Criteria 2.0. The patient underwent an extensive evaluation, including genetic testing, cerebrospinal fluid (CSF) analysis and amyloid PET imaging.
RESULTS: CSF analysis and amyloid PET imaging corroborated CAA diagnosis. Genetic testing identified an undescribed heterozygous c.124G > A (p.Gly42Ser) TTR variant, absent from population databases, within a region known for pathogenic mutations. Family genetic testing revealed the same mutation in the patient's father, who had a history of cerebral haemorrhage.
DISCUSSION: To our knowledge, this case represents one of the first documented examples of a TTR gene variant exclusively associated with CAA, in the absence of systemic amyloidosis. These findings suggest the existence of TTR variants that may result in a brain-restricted amyloid pathology. Genetic screening for TTR mutations should be considered in familial cases of CAA to refine diagnostic accuracy and guide clinical management strategies.
METHODS: A 56-year-old man presented with a history of right fronto-parietal intracerebral haemorrhage and recurrent transient episodes of right arm paraesthesia. Based on clinical and radiological presentation, a probable CAA diagnosis was established according to Boston Criteria 2.0. The patient underwent an extensive evaluation, including genetic testing, cerebrospinal fluid (CSF) analysis and amyloid PET imaging.
RESULTS: CSF analysis and amyloid PET imaging corroborated CAA diagnosis. Genetic testing identified an undescribed heterozygous c.124G > A (p.Gly42Ser) TTR variant, absent from population databases, within a region known for pathogenic mutations. Family genetic testing revealed the same mutation in the patient's father, who had a history of cerebral haemorrhage.
DISCUSSION: To our knowledge, this case represents one of the first documented examples of a TTR gene variant exclusively associated with CAA, in the absence of systemic amyloidosis. These findings suggest the existence of TTR variants that may result in a brain-restricted amyloid pathology. Genetic screening for TTR mutations should be considered in familial cases of CAA to refine diagnostic accuracy and guide clinical management strategies.